Evidence map›Paper›PMID 39413143›Full record

ArticlePLoS pathogens2024

8-Oxoguanine DNA Glycosylase1 conceals oxidized guanine in nucleoprotein-associated RNA of respiratory syncytial virus.

Lang Pan, Ke Wang, Wenjing Hao, Yaoyao Xue, Xu Zheng, Ritwika S Basu, Tapas K Hazra, Azharul Islam, Yashoda Hosakote, Bing Tian and 3 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lang PanDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Ke WangDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Wenjing HaoDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Yaoyao XueDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Xu ZhengDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Ritwika S BasuDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Tapas K HazraDepartment of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Azharul IslamDepartment of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Yashoda HosakoteDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Bing TianInstitute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China.
Matthieu G GagnonDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Xueqing BaDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
Istvan BoldoghDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.

Funding

Virus, Tissue Culture and ImmunoassayP01AI062885 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI BOLDOGH, ISTVAN STEVEN · 2005 to 2022
$23.9M
Nanoparticle-encapsulated Epigenetic Inhibitors for Treatment of Inflammatory Bowel DiseasesR21AI176297 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RYTTING, ERIK, TIAN, BING · 2024 to 2025
$430k
NIAID NIH HHS P01 AI062885NIAID NIH HHS R21 AI176297
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV), along with other prominent respiratory RNA viruses such as influenza and SARS-CoV-2, significantly contributes to the global incidence of respiratory tract infections. These pathogens induce the production of reactive oxygen species (ROS), which play a crucial role in the onset and progression of respiratory diseases. However, the mechanisms by which viral RNA manages ROS-induced base oxidation remain poorly understood. Here, we reveal that 8-oxo-7,8-dihydroguanine (8-oxoGua) is not merely an incidental byproduct of ROS activity but serves as a strategic adaptation of RSV RNA to maintain genetic fidelity by hijacking the 8-oxoguanine DNA glycosylase 1 (OGG1). Through RNA immunoprecipitation and next-generation sequencing, we discovered that OGG1 binding sites are predominantly found in the RSV antigenome, especially within guanine-rich sequences. Further investigation revealed that viral ribonucleoprotein complexes specifically exploit OGG1. Importantly, inhibiting OGG1's ability to recognize 8-oxoGua significantly decreases RSV progeny production. Our results underscore the viral replication machinery's adaptation to oxidative challenges, suggesting that inhibiting OGG1's reading function could be a novel strategy for antiviral intervention.

Indexed as

DNA GlycosylasesRespiratory Syncytial Virus InfectionsRNA, ViralGuanineHumansOxidation-ReductionReactive Oxygen SpeciesRespiratory Syncytial Virus, HumanVirus Replication8-hydroxyguanineDNA GlycosylasesGuanineoxoguanine glycosylase 1, humanReactive Oxygen SpeciesRNA, Viral

Identifiers

PMID39413143
PMCPMC11515973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.